menu
Introduction
  • The Biotherapeutic Translational Research Center (BTRC) is focused on fostering personalized treatment for rare and incurable diseases through development and implementation of new therapeutic platform technology and translational research studies. The primary mission of the BTRC is to stimulate high-quality clinical and translational research that seeks to enhance the care of cancer, diabetes, and cardio-neurodegenerative diseases. All BTRC faculty are dedicated to several translational projects aimed at design, discovery, and development of tailored biotherapeutics in cancer, vascular, stem cell, and metabolic research.
Research Areas
  • Mining of theranostic targets for vascular/metabolic diseases and cancer
  • Development of Biopharmaceuticals (antibody/protein) for vascular and cancer therapy
  • Discovery of recombinant protein with high efficiency and high productivity
  • Process development for the efficient biopharmaceuticals production
  • Finding out the resistance to drug and metastasis regulation and development of control technology
Head
Investigator
Name Position Tel / Email Detail
Jangwook Lee Associate Director / Detail

Tel

042-860-4123

Email

jlee@kribb.re.kr

Achievements
  • Development of first in class therapeutic antibody for vascular diseases and cancer
  • Identification of a protein phosphatase controlling vascular inflammation and metabolic diseases
  • Finding out the factors that regulate resistance to drugs and metastasis, development of control technology and establishment of basic-clinical translational research
  • Development of tumor-specific antibody-protein conjugates for therapeutic angiogenesis & anticancer therapy
  • Establishment of efficient production system for useful recombinant protein in serum-free suspended mammalian cells
  • Development of optimized purification system
  • Development of HIF inhibitor controlling cancer metabolism
  • Identifying non-coding RNAs, targets and functions in cancer
  • Development of biocompatible drug delivery system that can address adverse drug reactions and achieve targeted therapeutic success
  • Establishment of pig T- and B- cell knock out cell lines
  • Establishment of genetically modified cell lines to produce mini-pigs for Xenotransplantation
  • Development of disease mouse models
  • Advanced cultivation of microalgae and wastewater treatment
  • Mechanism of algal bloom and its control
  • High-efficiency production of useful recombinant protein by transient expression plant cell suspension culture system
  • Establishment of plant cell & tissue culture for the over-production of secondary metabolites derived from native herbal plants
  • The high quality reference genomes of Cucurbit crops
  • Viral vectors for expression of foreign proteins in plants
Selected Publications
  • Fluorescent nanoswitch for monitoring specific pluripotency-related microRNAs of induced pluripotent stem cells : development of polyethyleneimine-oligonucleotide hybridization probes.
    • Nano Res. 110(8):2545-2559.
    • Jeong Ki Min (Co-corresponding)
  • L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma.
    • Oncotarget. 8(9):15441-15452.
    • Jeong Ki Min (Co-corresponding)
  • Improvement of anti-cancer drug efficacy via thermosensitive hydrogel in peritoneal carcinomatosis in gastric cancer.
    • Oncotarget. 8(65):108848-108858.
    • Tae Su Han (Co-first)
  • Investigation of relationship between EBNA-1 expression level and specific foreign protein productivity in transient gene expression of HEK293 cells.
    • Process Biochem. 55:182-186.
    • Yeon-Gu Kim (Co-corresponding)